Rocket Pharmaceuticals, Inc. (FRA:9IP1)

Market Cap	317.00M -71.3%
Revenue (ttm)	n/a
Net Income	-205.33M
EPS	-1.91
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	47
Open	2.758
Previous Close	2.786
Day's Range	2.758 - 2.758
52-Week Range	1.778 - 10.455
Beta	n/a
RSI	45.27
Earnings Date	Feb 27, 2026

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 299
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9IP1

Financial Performance

Financial numbers in USD